- Home
- LVLU vs KPRX Comparison
LVLU vs KPRX Comparison
Compare LVLU & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- KPRX
- Stock Information
- Founded
- LVLU 1996
- KPRX 1998
- Country
- LVLU United States
- KPRX United States
- Employees
- LVLU N/A
- KPRX N/A
- Industry
- LVLU Catalog/Specialty Distribution
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LVLU Consumer Discretionary
- KPRX Health Care
- Exchange
- LVLU Nasdaq
- KPRX Nasdaq
- Market Cap
- LVLU 11.3M
- KPRX 9.2M
- IPO Year
- LVLU 2021
- KPRX N/A
- Fundamental
- Price
- LVLU $4.58
- KPRX $2.65
- Analyst Decision
- LVLU Hold
- KPRX Strong Buy
- Analyst Count
- LVLU 1
- KPRX 1
- Target Price
- LVLU $15.00
- KPRX $10.00
- AVG Volume (30 Days)
- LVLU 163.6K
- KPRX 51.3K
- Earning Date
- LVLU 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- LVLU N/A
- KPRX N/A
- EPS Growth
- LVLU N/A
- KPRX N/A
- EPS
- LVLU N/A
- KPRX N/A
- Revenue
- LVLU $292,337,000.00
- KPRX N/A
- Revenue This Year
- LVLU N/A
- KPRX N/A
- Revenue Next Year
- LVLU $2.53
- KPRX N/A
- P/E Ratio
- LVLU N/A
- KPRX N/A
- Revenue Growth
- LVLU N/A
- KPRX N/A
- 52 Week Low
- LVLU $2.98
- KPRX $2.25
- 52 Week High
- LVLU $28.05
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- LVLU 55.24
- KPRX 51.08
- Support Level
- LVLU $3.69
- KPRX N/A
- Resistance Level
- LVLU $6.40
- KPRX $2.80
- Average True Range (ATR)
- LVLU 0.62
- KPRX 0.11
- MACD
- LVLU 0.10
- KPRX -0.10
- Stochastic Oscillator
- LVLU 35.16
- KPRX 91.07
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.